Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GenSight Biologics SA

www.gensight-biologics.com

Latest From GenSight Biologics SA

Regenerative Medicines And Advanced Therapies: Progress, Problems And Promise

The Alliance for Regenerative Medicine’s Q3 report illustrates just how far the sector has come in the 10 years since the organization’s founding. The number of therapies in the pipeline has ballooned, in parallel with financing for development activities.

Regenerative Medicine Research and Development Strategies

GenSight Undeterred By Gene Therapy’s Placebo Puzzle

Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain

Gene Therapy Ophthalmic

ReNeuron's Cell Therapy Garners Excitement In RP-Related Vision Loss

A surprisingly strong improvement in vision has accompanied the use of proprietary stem cells in the first three retinitis pigmentosa patients in a US Phase II study, intriguing the UK biotech, ReNeuron, and maybe attracting development partners too.

 

Clinical Trials Ophthalmic

GenSight Sees Positives In Pivotal RESCUE Trial, Despite Missing Primary Endpoint

The company's gene therapy didn't hit the primary endpoints in either of its two Phase III studies in a severe genetic retinal disease reported so far, but a third trial designed through a special protocol assessment with the US FDA is ongoing.

Clinical Trials FDA
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • GenSight Biologics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • GenSight Biologics SA
  • Senior Management
  • Bernard Gilly, PhD, CEO
    Thomas Gidoin, CFO
    Didier Pruneau, PhD, CSO
    Magali Taiel, MD, CMO
  • Contact Info
  • GenSight Biologics SA
    Phone: (0)1 76 21 72 20
    74, rue du Faubourg Saint-Antoine
    Paris, 75012
    France
UsernamePublicRestriction

Register